AU2018270926C1 - Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods - Google Patents

Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods Download PDF

Info

Publication number
AU2018270926C1
AU2018270926C1 AU2018270926A AU2018270926A AU2018270926C1 AU 2018270926 C1 AU2018270926 C1 AU 2018270926C1 AU 2018270926 A AU2018270926 A AU 2018270926A AU 2018270926 A AU2018270926 A AU 2018270926A AU 2018270926 C1 AU2018270926 C1 AU 2018270926C1
Authority
AU
Australia
Prior art keywords
conjugate
cells
dose
composition
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018270926A
Other languages
English (en)
Other versions
AU2018270926B2 (en
AU2018270926A1 (en
Inventor
Peiwen Kuo Brewer
Peter Benedict Kirk
Ping Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of AU2018270926A1 publication Critical patent/AU2018270926A1/en
Application granted granted Critical
Publication of AU2018270926B2 publication Critical patent/AU2018270926B2/en
Priority to AU2022203691A priority Critical patent/AU2022203691B2/en
Publication of AU2018270926C1 publication Critical patent/AU2018270926C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2018270926A 2017-05-15 2018-05-15 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods Active AU2018270926C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022203691A AU2022203691B2 (en) 2017-05-15 2022-05-31 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762506494P 2017-05-15 2017-05-15
US62/506,494 2017-05-15
US201762536966P 2017-07-25 2017-07-25
US62/536,966 2017-07-25
US201762582186P 2017-11-06 2017-11-06
US62/582,186 2017-11-06
US201862648240P 2018-03-26 2018-03-26
US62/648,240 2018-03-26
PCT/US2018/032817 WO2018213341A1 (en) 2017-05-15 2018-05-15 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022203691A Division AU2022203691B2 (en) 2017-05-15 2022-05-31 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

Publications (3)

Publication Number Publication Date
AU2018270926A1 AU2018270926A1 (en) 2019-11-07
AU2018270926B2 AU2018270926B2 (en) 2022-04-07
AU2018270926C1 true AU2018270926C1 (en) 2022-10-27

Family

ID=64274790

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018270926A Active AU2018270926C1 (en) 2017-05-15 2018-05-15 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
AU2022203691A Active AU2022203691B2 (en) 2017-05-15 2022-05-31 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022203691A Active AU2022203691B2 (en) 2017-05-15 2022-05-31 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

Country Status (10)

Country Link
US (2) US12036283B2 (enExample)
EP (1) EP3624827A4 (enExample)
JP (3) JP7316222B2 (enExample)
KR (2) KR20250057110A (enExample)
CN (2) CN119700941A (enExample)
AU (2) AU2018270926C1 (enExample)
CA (1) CA3060410A1 (enExample)
IL (2) IL318018A (enExample)
MX (2) MX2019013621A (enExample)
WO (1) WO2018213341A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
JP7611136B2 (ja) * 2018-11-09 2025-01-09 ネクター セラピューティクス 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬
IL286971B1 (en) * 2019-04-05 2026-08-01 Nektar Therapeutics Long-acting interleukin-15 receptor agonist in combination with chimeric antigen receptor (CAR-T) cells
BR112021022666A2 (pt) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Frações de separação e seus métodos e uso
SG11202111409YA (en) 2019-05-20 2021-12-30 Cytune Pharma IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
WO2022090203A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
KR20230096047A (ko) 2020-10-26 2023-06-29 싸이튠 파마 비흑색종 피부암 치료용 IL-2/IL-15Rβγ 작용제
JP2024526080A (ja) 2021-06-23 2024-07-17 サイチューン ファーマ インターロイキン１５多様体
US20240350589A1 (en) 2021-08-13 2024-10-24 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
WO2024173571A1 (en) * 2023-02-14 2024-08-22 Amcyte Pharma, Inc. Interleukin formulations for in vivo use
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102145178A (zh) * 2011-04-15 2011-08-10 北京凯因科技股份有限公司 Peg化白介素15
WO2015153753A2 (en) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugates of an il-15 moiety and a polymer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6110721A (en) 1993-11-12 2000-08-29 Gilead Sciences, Inc. Polypeptides and coagulation therapy
WO1995027722A1 (en) 1994-04-06 1995-10-19 Immunex Corporation Interleukin-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
RS20050501A (sr) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati citokina,hemokina,faktora rasta, polipeptidnih hormona i njihovih antagonista sa očuvanom aktivnošću vezivanja receptora
ATE444984T1 (de) 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
US7910661B2 (en) 2003-01-06 2011-03-22 Nektar Therapeutics Thiol-selective water-soluble polymer derivatives
US7276478B2 (en) 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
US20060057680A1 (en) 2004-08-11 2006-03-16 Zheng Xin X Mutant interleukin-15 polypeptides
US20060104945A1 (en) 2004-10-05 2006-05-18 Choi Yong S Enhancement of B cell proliferation by IL-15
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
CA2611823C (en) 2005-06-16 2013-07-30 Nektar Therapeutics Al, Corporation Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
CN106046370A (zh) 2007-02-28 2016-10-26 塞瑞纳治疗公司 聚噁唑啉poz化合物、合成其的方法、以及靶分子‑poz偶联物
LT2237799T (lt) 2008-02-01 2019-07-25 Ascendis Pharma A/S Provaistas, apimantis besiskaidantį linkerį
EP2350118B1 (en) * 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
JP5775820B2 (ja) 2008-10-21 2015-09-09 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 遊離可能ｐｅｇ試薬を有するプロドラッグｐｅｇタンパク質結合体において活性成分（インビトロ脱ペグ化）を決定する方法
TWI534152B (zh) 2010-07-30 2016-05-21 巴克斯特國際公司 用於肟連接的親核性催化劑
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
WO2014201378A1 (en) 2013-06-13 2014-12-18 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
EP3206713A4 (en) * 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
WO2017062832A1 (en) * 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102145178A (zh) * 2011-04-15 2011-08-10 北京凯因科技股份有限公司 Peg化白介素15
WO2015153753A2 (en) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugates of an il-15 moiety and a polymer

Also Published As

Publication number Publication date
IL270634A (en) 2019-12-31
KR20250057110A (ko) 2025-04-28
CN119700941A (zh) 2025-03-28
AU2022203691B2 (en) 2023-10-12
KR20200003922A (ko) 2020-01-10
WO2018213341A1 (en) 2018-11-22
JP2025111770A (ja) 2025-07-30
IL318018A (en) 2025-02-01
IL270634B2 (en) 2025-06-01
JP2023082218A (ja) 2023-06-13
JP7772733B2 (ja) 2025-11-18
EP3624827A4 (en) 2021-03-03
IL270634B1 (en) 2025-02-01
AU2022203691A1 (en) 2022-06-16
JP7316222B2 (ja) 2023-07-27
CA3060410A1 (en) 2018-11-22
EP3624827A1 (en) 2020-03-25
JP2020519676A (ja) 2020-07-02
KR102798243B1 (ko) 2025-04-18
US20240424115A1 (en) 2024-12-26
US12036283B2 (en) 2024-07-16
US20200078467A1 (en) 2020-03-12
MX2024009988A (es) 2024-08-27
AU2018270926B2 (en) 2022-04-07
MX2019013621A (es) 2020-01-13
AU2018270926A1 (en) 2019-11-07
CN111093688A (zh) 2020-05-01
CN111093688B (zh) 2025-09-16

Similar Documents

Publication Publication Date Title
AU2022203691B2 (en) Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
AU2015240806B2 (en) Conjugates of an IL-15 moiety and a polymer
KR102591732B1 (ko) Ｉｌ-2 부분 및 중합체의 접합체
KR20170125839A (ko) Ｉｌ-7 부분 및 중합체의 접합체
EA043667B1 (ru) Длительно действующие агонисты рецептора интерлейкина-15, связанные с ними композиции и способы их получения и применения
HK1235666B (en) Conjugates of il-15 and branched polyethylene glycol
HK1235666A1 (en) Conjugates of il-15 and branched polyethylene glycol

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 JUN 2022

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 JUN 2022

FGA Letters patent sealed or granted (standard patent)